Pharmacy Week in Review: February 26, 2016

The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.

Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.

A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.

Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD

The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.

VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.

Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.

A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.